Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment …

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …

22 hours ago · LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on …

Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of …

Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with …

Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its …

Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) …

Dec 22, 2024 · Conducted as part of the company’s phase 3 clinical programme, this trial highlights the efficacy of CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and …

Nov 18, 2024 · CagriSema is an experimental drug being developed by Novo Nordisk. It is currently undergoing late-stage clinical trials for the treatment of obesity and type 2 diabetes. …

Nov 6, 2024 · Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its …